Want to see A full AI Analyst Report?
Revenue by Segment
Breaks down revenue by business segment, offering a view into which divisions are performing well and contributing most to the company's overall financial health.Agilent’s CrossLab has emerged as the durable growth driver—its sharp step-up reflects recent M&A and the conversion of instrument placements into higher-margin service revenues (management flags a 12–18 month conversion lag), which substantiates the raised guidance and cash returns. By contrast Life Sciences & Applied Markets remains cyclical and below its 2022 peak as instrument replacement cadence, CDMO/ATD lapping and regional variability drive volatility. Diagnostics & Genomics is steady but sensitive to end‑market swings. Remember Q3 tariff refunds and Biocare tailwinds are one‑time boosts; underlying Ignite pricing and China momentum must persist to sustain the run.
Date | Life Sciences and Applied Markets Group | Agilent Crosslab Group | Diagnostics and Genomics Group |
|---|---|---|---|
Sep 30, 2026 | $746.00M | $786.00M | $346.00M |
Jun 30, 2026 | $732.00M | $759.00M | $344.00M |
Mar 31, 2026 | $679.00M | $758.00M | $361.00M |
Dec 31, 2025 | $755.00M | $755.00M | $351.00M |
Sep 30, 2025 | $670.00M | $744.00M | $324.00M |
Jun 30, 2025 | $654.00M | $713.00M | $301.00M |
Mar 31, 2025 | $647.00M | $696.00M | $338.00M |
Dec 31, 2024 | $833.00M | $426.00M | $442.00M |
Sep 30, 2024 | $782.00M | $411.00M | $385.00M |
Jun 30, 2024 | $754.00M | $402.00M | $417.00M |